CAR-T Cell Therapy Market Size, Trends, Growth, Opportunities 2024-2032 | Gilead Sciences, Inc., AbbVie Inc., Novartis AG, and Bristol-Myers Squibb Company

The global CAR-T cell therapy market size was valued at USD 4.38 billion in 2023. The market is projected to grow from USD 6.37 billion in 2024 to USD 16.35 billion by 20322, exhibiting a CAGR of 12.5% during the forecast period (2024-2032).

The CAR-T cell therapy market is experiencing significant growth as this innovative treatment offers new hope for patients with certain cancers. This press release explores a recent key industry development, leading segment, and future outlook for this transformative medical technology.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/car-t-cell-therapy-market-108455

𝗠𝗮𝘅 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗕𝗿𝗶𝗻𝗴𝘀 𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗼 𝗗𝗲𝗹𝗵𝗶-𝗡𝗖𝗥:

A significant development in December 2023 saw Max Healthcare partner with ImmunoACT to introduce CAR-T cell therapy in Delhi-NCR, India. This move expands access to this potentially life-saving treatment for patients with lymphomas and leukaemias in the region. The increasing availability of CAR-T cell therapy signifies a brighter future for cancer treatment.

𝗧𝗼𝗽 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗮𝗿𝗸𝗲𝘁:

• Gilead Sciences, Inc. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (Janssen Global Services, LLC) (U.S.)
• Caribou Biosciences, Inc. (U.S.)
• CARSgenTherapeutics Co., Ltd (China)
• JW Therapeutics (Shanghai) Co., Ltd. (China)
• Cartesian Therapeutics, Inc. (U.S.)
• Aurora Biopharma (U.S.)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 𝗮𝗻𝗱 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

Several factors are driving the growth of the CAR-T cell therapy market:

• 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀: CAR-T cell therapy offers a promising treatment option for patients with aggressive blood cancers who may have exhausted other options.
• 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵: Increased investment in research and development is leading to advancements in CAR-T cell therapies and their applications.
• 𝗥𝗶𝘀𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗣𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲: The increasing incidence of cancer globally is creating a larger patient population potentially benefiting from CAR-T cell therapy.

However, certain challenges remain:

• 𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: CAR-T cell therapy is a complex and expensive treatment, limiting accessibility for some patients.
• 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: The personalized nature of CAR-T cell therapy can pose logistical challenges in manufacturing and treatment delivery.
• 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀: CAR-T cell therapy can have serious side effects, requiring careful patient monitoring and management.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁: https://www.fortunebusinessinsights.com/car-t-cell-therapy-market-108455

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲:

For a comprehensive understanding of the CAR-T cell therapy market, Fortune Business Insights' report offers in-depth analysis on:

• 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗼𝘄𝘁𝗵 𝗣𝗿𝗼𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀: The report provides detailed market size and growth forecasts for the CAR-T cell therapy market over the forecast period.
• 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: The report segments the market based on drug type (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene darolumab), application (acute lymphoblastic leukaemia, non-Hodgkin lymphoma), and end-user (hospitals, specialized cancer centres).
• 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲: The report identifies key players in the market and analyzes their competitive strategies.
• 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: The report provides insights into the growth potential of CAR-T cell therapy in different geographical regions.

𝗔𝘅𝗶𝗰𝗮𝗯𝘁𝗮𝗴𝗲𝗻𝗲 𝗖𝗶𝗹𝗼𝗹𝗲𝘂𝗰𝗲𝗹 𝗟𝗲𝗮𝗱𝘀 𝘁𝗵𝗲 𝗪𝗮𝘆:

The axicabtagene ciloleucel segment dominates the CAR-T cell therapy market based on drug type. This dominance is likely to continue throughout the forecast period. Axicabtagene ciloleucel is a commercially available CAR-T cell therapy for treating a specific type of lymphoma.

𝗔 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The CAR-T cell therapy market exhibits a dynamic competitive landscape. Established pharmaceutical companies are actively involved in research and development, while newer players are emerging with innovative CAR-T cell therapy approaches.

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆:

The CAR-T cell therapy market is poised for significant growth as research efforts lead to more effective and accessible CAR-T cell therapies for a wider range of cancers. With increasing global partnerships and advancements in manufacturing, CAR-T cell therapy has the potential to revolutionize cancer treatment and offer new hope for millions of patients.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/car-t-cell-therapy-market-108455

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.